MitoTEMPOL
Based on 4 publication(s) in Google Scholar
MitoTEMPOL is a mitochondria-targeted superoxide scavenger. MitoTEMPOL accumulates in mitochondria via membrane potential and locally scavenges superoxide anions. MitoTEMPOL alleviates hepatic oxidative stress and alterations in genes related to autophagy in STZ (HY-13753)-induced diabetic models. MitoTEMPOL inhibits diaphragmatic mitochondrial dysfunction and activation of proteolytic pathways in sepsis models. MitoTEMPOL also alleviates AGEs (HY-NP165)-induced ferritinophagy-dependent ferroptosis in human umbilical vein endothelial cells. MitoTEMPOL is used in research related to diabetes, sepsis, and vascular endothelial ferroptosis.
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 1101113-39-6
- Formula: C32H42BrNO2P*
- Molecular Weight:583.56
-
Storage:
-20°C, sealed storage, away from moisture and light, under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications Citing Use of MedChemExpress (MCE) MitoTEMPOL
More
Biological Activity
Description
In Vitro
MitoTEMPOL (10 mg/l; 24 h) eliminates cytokine-induced superoxide production in C2C12 myocytes[2].
MitoTEMPOL (pretreatment for 1 h) scavenges ROS and alleviates AGEs (HY-NP165)-induced ferroptosis and ferritinophagy in HUVECs[3].
MitoTEMPOL (10 mg/l; 24 h) prevents cytokine-induced reduction in C2C12 myotube width[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MitoTEMPOL (10 mg/kg; i.p.; administered twice, after surgery and 24 h later) prevents sepsis-induced diaphragmatic weakness, mitochondrial dysfunction, proteolytic enzyme activation, and myosin heavy chain loss[2].
MitoTEMPOL (10 mg/kg; i.p.; administered immediately after surgery or with the first injection delayed until 6 h post-surgery (followed by a second injection 24 h later)) is as effective as immediate injection in preventing sepsis-induced diaphragm weakness[2].
MitoTEMPOL (10 mg/kg; i.p.; administered at the time of CLP induction) blocks the early decrease in aconitase activity and prevents the late activation of proteases in the septic diaphragm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (Male, 8 weeks old, 210 g, STZ-induced diabetes)[1]
-
Dosage:100 mg/kg BW/day
-
Administration:p.o.; 5 times a week; 5 weeks
-
Result:Reduced lipid droplets in both this compound-only and STZ + this compound groups compared to control and STZ groups.
Increased Parkin gene expression 1.22-fold in this compound-only group and 1.22-fold in STZ + this compound group compared with control.
Increased BNIP3 gene expression 1.28-fold in this compound-only group compared with control.
Increased BNIP3 gene expression 1.26-fold in STZ + this compound group compared with STZ and 1.32-fold compared with control.
Increased Mfn1 gene expression 1.36-fold in this compound-only group compared with control and 1.21-fold compared with STZ group.
Increased Mfn1 gene expression 1.26-fold in STZ + this compound group compared with STZ and 1.23-fold compared with control.
Increased LC3 gene expression 1.26-fold in this compound-only group compared with control and 1.29-fold compared with STZ group.
Increased LC3 gene expression 1.24-fold in STZ + this compound group compared with STZ group.
-
Animal Model:ICR (CD-1) (Male, 25-30 g, Cecal ligation puncture (CLP) induced sepsis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; after surgery and again at 24 hours
-
Result:Blocked the sepsis-induced reduction in diaphragm strength, with force at 50 Hz averaging 27.0 N/cm2 for CLP + this compound versus 12.6 N/cm2 for CLP.
Maintained diaphragm force at the end of repetitive contraction trials at 12.6 versus 4.0 for CLP.
Prevented CLP-induced reductions in mitochondrial function, increasing state 3 oxygen consumption, RCR, and ATP production rates to levels significantly higher than for CLP septic animals.
Completely prevented CLP-induced increases in diaphragm calpain activity (355% increase in CLP), caspase 3 activity (352% increase in CLP), and 20S proteasome activity (226% increase in CLP).
Prevented the sepsis-induced reduction in diaphragm myosin heavy chain levels.
-
Animal Model:ICR (CD-1) (Male, 25-30 g, Cecal ligation puncture (CLP) induced sepsis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; at 6 hours after surgery and again at 24 hours after surgery
-
Result:Prevented sepsis-induced loss of diaphragm strength, with diaphragm specific force generation for CLP + delayed this compound groups significantly higher than levels for the CLP group.
Showed similar findings for force measurements during repetitive contraction trials, with force at every time point similar for delayed and immediate this compound groups, and both significantly higher than CLP animals.
-
Animal Model:ICR (CD-1) (Male, 25-30 g, Cecal ligation puncture (CLP) induced sepsis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; at the time of induction of CLP
-
Result:Blocked early reductions in aconitase activity at all time points and prevented proteolytic enzyme activation at 24 hours.
Had higher aconitase levels at all time points after CLP as compared to saline treated CLP groups.
Reduced all three proteolytic enzyme activities at the 24 hour time point for caspase, calpain and 20S proteasome activities.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1101113-39-6
-
Appearance Solid
-
Molecular Weight 583.56
-
Formula C32H42BrNO2P*
-
Color Brown to orange
-
SMILES
[O]N1C(C)(CC(CC1(C)C)OCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)C.[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light, under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. [Abstract]2026 Jul:94:104228. PMID: 42176503 -
Cell Rep Med
Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis. [Abstract]2025 Sep 25:102371. PMID: 41005298 -
Int J Dent
The ROS/CaMK II/β-Catenin Signaling Axis Affects the Osteogenic Potential of BMSCs and Disrupts Implant Osseointegration: An In Vitro Study. [Abstract]2025 Aug 15:2025:5566776. PMID: 40861924 -
bioRxiv
2025 Nov 13:2025.11.11.687895. PMID: 41292779
Solvent & Solubility
In Vitro:
DMF : 50 mg/mL (85.68 mM; Need ultrasonic and warming)
Ethanol : 50 mg/mL (85.68 mM; Need ultrasonic and warming)
DMSO : 50 mg/mL (85.68 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / Ethanol / DMSO | 1 mM | 1.7136 mL | 8.5681 mL | 17.1362 mL | 42.8405 mL |
| 5 mM | 0.3427 mL | 1.7136 mL | 3.4272 mL | 8.5681 mL | |
| 10 mM | 0.1714 mL | 0.8568 mL | 1.7136 mL | 4.2840 mL | |
| 15 mM | 0.1142 mL | 0.5712 mL | 1.1424 mL | 2.8560 mL | |
| 20 mM | 0.0857 mL | 0.4284 mL | 0.8568 mL | 2.1420 mL | |
| 25 mM | 0.0685 mL | 0.3427 mL | 0.6854 mL | 1.7136 mL | |
| 30 mM | 0.0571 mL | 0.2856 mL | 0.5712 mL | 1.4280 mL | |
| 40 mM | 0.0428 mL | 0.2142 mL | 0.4284 mL | 1.0710 mL | |
| 50 mM | 0.0343 mL | 0.1714 mL | 0.3427 mL | 0.8568 mL | |
| 60 mM | 0.0286 mL | 0.1428 mL | 0.2856 mL | 0.7140 mL | |
| 80 mM | 0.0214 mL | 0.1071 mL | 0.2142 mL | 0.5355 mL |